LMT503 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease


Clinical trials : 2,442 Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05659953
(ClinicalTrials.gov)
March 1, 202325/11/2022LMT503 First-in-human SAD, MAD, and FE StudyA Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LMT503 in Healthy SubjectsColitis, Ulcerative;Crohn Disease;Inflammatory Bowel DiseaseDrug: LMT503;Drug: PlaceboLmito Therapeutics Inc.NULLNot yet recruiting18 Years65 YearsAll72Phase 1Netherlands